Table 4.
Subgroup analysis of CRC mortality reduction after endoscopic screening
| Subgroups | No. of studies | Pooled RR (95% CI) | Z | P | Heterogeneity | |
|---|---|---|---|---|---|---|
| I2 (%) | Ph | |||||
| Intervention | 3.34 | |||||
| Screening 8,27,35,37,39,45,46,53,55,56 | 10 | 0.362 (0.339-0.386) | 12.11 | 0.000 | 31.0 | |
| Screening/diagnostic and Various* 24,25,36,47 | 4 | 0.397 (0.369-0.427) | 5.09 | 0.008 | 73.5 | |
| Study design | 5.99 | |||||
| Cochort 8,35,36,37,39,45-47 | 8 | 0.356 (0.333-0.381) | 9.89 | 0.000 | 45.0 | |
| (Nested) case-control 24,25,27,53,55,56 | 6 | 0.402 (0.375-0.432) | 7.87 | 0.000 | 44.5 | |
| Country | 8.08 | |||||
| Western 8,24,25,27,35,37,39,45-47,53,55,56 | 13 | 0.378 (0.360-0.397) | 18.09 | 0.000 | 38.9 | |
| Asia 36 | 1 | 0.080 (0.027-0.233) | 4.63 | 0.000 | NA | |
| Sample size | 3.97 | |||||
| ≤10,000 27,39,53,55,56 | 5 | 0.409 (0.311-0.537) | 4.06 | 0.000 | 54.4 | |
| 10,000-100,000 8,24,25,36,45,46 | 6 | 0.394 (0.368-0.423) | 8.94 | 0.000 | 58.1 | |
| ≥1 million 35,38,47 | 3 | 0.358 (0.334-0.384) | 4.62 | 0.000 | 34.5 | |
| Age | 0.20 | |||||
| 20-50 8,35,36,39,53,55 | 6 | 0.358 (0.284-0.451) | 4.07 | 0.000 | 71.7 | |
| ≥50 24,25,27,38,45-47,56 | 8 | 0.378 (0.360-0.397) | 21.95 | 0.001 | 29.2 | |
| Sex | 11.47 | |||||
| Male 8,25,36,47 | 4 | 0.440 (0.404-0.479) | 7.00 | 0.000 | 49.1 | |
| Female 8,25,36,47 | 4 | 0.351 (0.318-0.388) | 5.62 | 0.000 | 88.5 | |
NA = not applicable; RR = relative risk; CI = confidence interval.